Clinical Trial: Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura
Study Status: Enrolling by invitation
Recruit Status: Unknown status
Study Type: Observational
Official Title: Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura
Brief Summary:
Henoch Schonlein Purpura (HSP), vasculitis of small vessels with deposits of IgA, is considered by many authors as the systemic form of Berger's disease (IgA-N). IgA-N is characterized by IgA1 deposits in mesangial areas associated with mesangial proliferation. These two diseases remain the leading cause of ESRD by primitive glomerulopathy in Western countries. In recent years, considerable progress has been made in understanding the pathophysiological mechanisms of IgA-N. However, only a high rate of proteinuria at one year or the presence of severe glomerular inflammation on renal biopsy remain predictors of long term renal function. Moreover, the high variability of HSP clinical expression, from few purpura skin lesions that evolve favourably spontaneously, to rapidly progressive renal failure, remains so far unexplained but suggests the existence of individual genetic susceptibility.
In the first part of the study, we will study key factors based on physiopathological data obtained by our laboratory as well as by other groups. The second part of the study concerns genetic factors. Although the candidate genes that may confer a particular susceptibility to the disease, to progress to ESRD or respond to treatment are many, the genes involved in inflammation or controlling renin-angiotensin system are of particular interest.
We will apply these results by studying patients with HSP showing three distinct phenotypes (HSP with isolated cutaneous purpura or associated with minimal or severe renal disease) at diagnosis and after clinical remission.
The purpose of this study is to assess whether the phenotype at diagnosis is associated with the physiological markers and if one of them predicts a pejorative evolution of renal disease at 1 year. Meanwhile, study of polymorphism o
Detailed Summary:
Sponsor: Assistance Publique - Hôpitaux de Paris
Current Primary Outcome: Renal prognosis [ Time Frame: one time measure after a four hour writing session ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Assistance Publique - Hôpitaux de Paris
Dates:
Date Received: May 31, 2012
Date Started: April 2010
Date Completion: July 2014
Last Updated: April 22, 2014
Last Verified: July 2012
